OncoMatch/Clinical Trials/NCT05475925
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Is NCT05475925 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies DR-01 for lgll - large granular lymphocytic leukemia.
Treatment: DR-01 — This is a multicenter, first-in-human, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia or cytotoxic lymphomas
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Acute Lymphoblastic Leukemia
Prior therapy
Must have received: systemic therapy
Must have discontinued at least one prior line of systemic therapy
Must have received: systemic regimen
Subjects must have failed at least one prior systemic regimens
Cannot have received: immunosuppressive therapy for GVHD
Any immunosuppressive therapy for GVHD for subjects who are post allogeneic HSCT
Lab requirements
Blood counts
Kidney function
Liver function
Sufficient key organ performance and coagulation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Dren Investigational Site · Boston, Massachusetts
- Dren Investigational Site 1 · New York, New York
- Dren Investigational Site · Birmingham, Alabama
- Dren Investigational Site · Duarte, California
- Dren Investigational Site · Irvine, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05475925 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior immunosuppressive therapy for GVHD disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify